GB202020285D0 - Treatment od disorders associated with loww BH4 bioavailablility - Google Patents
Treatment od disorders associated with loww BH4 bioavailablilityInfo
- Publication number
- GB202020285D0 GB202020285D0 GBGB2020285.9A GB202020285A GB202020285D0 GB 202020285 D0 GB202020285 D0 GB 202020285D0 GB 202020285 A GB202020285 A GB 202020285A GB 202020285 D0 GB202020285 D0 GB 202020285D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- loww
- bioavailablility
- treatment
- disorders associated
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2020285.9A GB202020285D0 (en) | 2020-12-21 | 2020-12-21 | Treatment od disorders associated with loww BH4 bioavailablility |
EP21839631.5A EP4262806A1 (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability |
IL303773A IL303773A (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability |
JP2023537676A JP2024502252A (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low BH4 bioavailability |
KR1020237024218A KR20230124967A (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low BH4 bioavailability |
MX2023007167A MX2023007167A (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability. |
PCT/GB2021/053382 WO2022136851A1 (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability |
AU2021406035A AU2021406035A1 (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability |
CA3202619A CA3202619A1 (en) | 2020-12-21 | 2021-12-21 | Treatment of disorders associated with low bh4 bioavailability |
CL2023001821A CL2023001821A1 (en) | 2020-12-21 | 2023-06-19 | Treatment of disorders associated with low bioavailability of bh4. |
CONC2023/0008648A CO2023008648A2 (en) | 2020-12-21 | 2023-06-29 | Treatment of disorders associated with low bioavailability of bh4 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2020285.9A GB202020285D0 (en) | 2020-12-21 | 2020-12-21 | Treatment od disorders associated with loww BH4 bioavailablility |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202020285D0 true GB202020285D0 (en) | 2021-02-03 |
Family
ID=74221139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2020285.9A Ceased GB202020285D0 (en) | 2020-12-21 | 2020-12-21 | Treatment od disorders associated with loww BH4 bioavailablility |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB202020285D0 (en) |
-
2020
- 2020-12-21 GB GBGB2020285.9A patent/GB202020285D0/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009830A (en) | Methods for the treatment of abnormal involuntary movement disorders. | |
MY192917A (en) | Compositions and methods of use for treating metabolic disorders | |
IL291272A (en) | Neuromodulation of the glossopharyngeal nerve to improve sleep disordered breathing | |
PH12016501802B1 (en) | Absorbent article | |
EP2485799A4 (en) | Extracranial implantable devices, systems and methods for the treatment of neurological disorders | |
SG11202011018PA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
GB201907283D0 (en) | Use of cannabidiol in the treatment of epileptic spams | |
SG11202011010YA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
SG11202100092QA (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS | |
MX354598B (en) | Use of neuregulin to treat peripheral nerve injury. | |
IL275499A (en) | Methods of treating metabolic disorders with fgf21 variants | |
EP3890753A4 (en) | Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh1 activity | |
GB201914034D0 (en) | Treatment of neurological disorders | |
GB202020285D0 (en) | Treatment od disorders associated with loww BH4 bioavailablility | |
ZA202205546B (en) | Methods for providing continuous therapy against pnag comprising microbes | |
IL285304A (en) | Methods for treating symptoms and disorders associated with lysosomal storage diseases | |
GB202108231D0 (en) | Treatment of disorders associated with low bh4 bioavaliability | |
IL309392A (en) | Retinal disorders | |
IL309393A (en) | Retinal disorders | |
GB202108756D0 (en) | Retinal disorders | |
GB202108759D0 (en) | Retinal disorders | |
GB202108760D0 (en) | Retinal disorders | |
GB202204231D0 (en) | Retinal Disorders | |
GB202204234D0 (en) | Retinal Disorders | |
GB202204230D0 (en) | Retinal Disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |